New combo offers hope for Drug-Resistant lung cancer
Disease control
Not yet recruiting
This study tests whether adding a new drug (capivasertib) to the standard drug osimertinib can help people with a specific type of advanced lung cancer that has stopped responding to treatment. About 53 adults with certain genetic changes in their tumors will receive the combinat…
Phase: PHASE1, PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated May 11, 2026 20:51 UTC